Jan graduated from Erasmus University Medical School in Rotterdam as a surgeon in 2000 and went on to work in Bernhoven Hospital in Uden in The Netherlands for 10 years. As a Healthcare entrepreneur and CEO, in 2013 he founded the Alexander Monro Hospital, Bilthoven, the first breast cancer hospital in Europe. In 2018 he co-founded the first focus clinic for prostate cancer: Reinier Haga Prostate Cancer Center, Delft.
Elmer graduated in Economics from Erasmus University in Rotterdam. After 5 years with PricewaterhouseCoopers in auditing and capital markets he joined F. Hoffmann-La Roche AG (Roche), a large pharmaceutical and diagnostics company that develops, manufactures and markets pharmaceutical and diagnostics products on a global scale. From 2003 to 2019 he served in various senior roles at Roche. Roles at Roche included Director of Finance, Commercial Director for the Middle East, Audit Director for Americas & CEMAI region.
Karen J. Williams
Karen is the founder of Karma Oncology, a niche provider of clinical development services. She has 30 years of clinical research experience and has worked in both the pharmaceutical and CRO industries during her career. She has a BSc (Hons) in biology and PhD in bioengineering both from the University of Strathclyde in Glasgow, Scotland. During her career, she has managed in excess of 150 clinical trials in a variety of indications More than 85 of those were oncology trials, which has led to her establishing Karma Oncology.
Ermond van Beek
Head of Pre-Clinical Research
Ermond van Beek is a senior researcher with 25 years’ clinical research experience at Leiden University Medical Center in The Netherlands. He obtained a doctorate degree (summa cum laude) on the thesis entitled: ‘Mechanism of action of bisposphonates’. Throughout his scientific career he has published widely and patented various inventions, including four patents concerning Coretag’s groundbreaking platform technology for specific binding to necrotic cells.
Chairman of the Board
For a few years Markwin studied Business at the Erasmus Universiteit Rotterdam, the Netherlands after which he launched his first business. As entrepreneur Markwin has a background in marketing, communications and as co-initiator and fundmanager and boardmember of two private equity funds which where supported by MeesPierson and F van Lanschot, two leading Dutch private banks in the Netherlands. Since the banking crisis, which led to the end of the era of leverage finance, Markwin focusses on financial and physical trading, life science and real-estate projects. With Coretag Markwin aims to contribute to the solution for cancer, the life threatening disease which causes so many casualties and which has a tremendous impact on all our lives.